HLX-109

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NameHLX-109
Drug Alias NameHLX-109
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionMitogen-activated protein kinase modulatorsInterleukin-1 receptor accessory protein inhibitorsMitogen-Activated Protein Kinase Kinase Kinase 14 modulators
TargetsMitogen-activated protein kinaseInterleukin-1 receptor accessory proteinMitogen-Activated Protein Kinase Kinase Kinase 14
Therapy Area/IndicationsInflammationAutoimmune DiseasesImmune System Diseases +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesU-mab Biopharma (Lianyungang) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Henlius Biotech Inc
Inactive CompaniesU-mab Biopharma (Lianyungang) Co Ltd
Active IndicationsInflammationAutoimmune DiseasesPsoriasis +[5] 
Inactive IndicationsImmune System Diseases

Other Information

ATC CodeN/A
Related LinksN/A